On January 24, 2019, Tangherlini, Giovanni; Kalinin, Dmitrii V.; Schepmann, Dirk; Che, Tao; Mykicki, Nadine; Staender, Sonja; Loser, Karin; Wuensch, Bernhard published an article.COA of Formula: C8H10N2 The title of the article was Development of novel quinoxaline-based κ-opioid receptor agonists for the treatment of neuroinflammation. And the article contained the following:
Neuroinflammatory disorders, such as multiple sclerosis or exptl. autoimmune encephalomyelitis (EAE), an established mouse model mimicking part of the human pathol., are characterized by inflammatory infiltrates containing T helper 1 (TH1) and TH17 cells, which cause demyelination and neurodegeneration. Disease onset and perpetuation are mediated by peripherally generated autoreactive T cells infiltrating into the central nervous system, where they are restimulated by antigen-presenting cells. Here, we show that newly designed peripherally active, potent, and selective κ-opioid receptor (KOR) agonists comprising the ethylenediamine KOR pharmacophore in a perhydroquinoxaline scaffold exhibit potent anti-inflammatory capacities in primary antigen presenting cells as well as T cells. In the EAE model, the secondary amine I and the triazole II were able to ameliorate disease severity and to delay disease onset by blocking effector T cell activation. Importantly, the beneficial effects were mediated via signaling through KOR because off-target effects were excluded by using KOR-deficient mouse mutants. The experimental process involved the reaction of 5,6,7,8-Tetrahydroquinoxaline(cas: 34413-35-9).COA of Formula: C8H10N2
The Article related to quinoxaline kappa opioid receptor agonist neuritis antiinflammatory multiple sclerosis, anti multiple sclerosis immunomodulator, Pharmacology: Structure-Activity and other aspects.COA of Formula: C8H10N2
Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider